// App-Quantinova.ai

411 : Bimekizumab Improves Signs and Symptoms Including Inflammation in Patients with Active Ankylosing Spondylitis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo Controlled Study

Researchers

Presenter

  • Désirée van der Heijde

Principal Investigators

  • Xenofon Baraliakos

  • Maxime Dougados

  • Matthew Brown

  • Denis Poddubnyy

  • Filip Van den bosch

  • Nigil Haroon

  • Huji Xu

  • Tetsuya Tomita

  • Lianne Gensler

  • Marga Oortgiesen

  • Carmen Fleurinck

  • Natasha de Peyrecave

  • Thomas Vaux

  • Alexander Marten

  • Atul Deodhar

Medical Centers

  • Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands, Leiden, Netherlands

  • Rheumazentrum Ruhrgebiet, Herne, Germany

  • Department of Rheumatology, Hôpital Cochin, Paris, France, Paris, France

  • Genomics England, London, United Kingdom

  • Medical Department for Gastroenterology, Infectious Diseases and Rheumatology, Charite - Universitatsmedizin Berlin, Berlin, Germany

  • Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium, VIB Center for Inflammation Research, Ghent, Belgium

  • Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada

  • Department of Hematology, Shanghai Changhai Hospital Affiliated to The 2nd Military Medical University, Shanghai, China

  • Department of Orthopaedic Biomaterial Science, Osaka University Graduate School of Medicine, Osaka, Japan, Suita Osaka, Japan

  • Department of Medicine, Division of Gastroenterology, University of California, San Francisco, San Franciso, California, United States

  • UCB Pharma, Raleigh, NC

  • UCB Pharma, Brussels, Belgium, Oosterzele, Belgium

  • UCB Pharma, Brussels, Belgium

  • UCB Pharma, Slough, UK Slough United Kingdom

  • UCB Pharma, Monheim am Rhein, Germany

  • Oregon Health & Science University, Portland, OR, USA, Portland, OR

Locations

  • Netherlands

  • Germany

  • France

  • United Kingdom

  • Belgium

  • Canada

  • China

  • Japan

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

Disease

  • Ankylosing spondylitis

Biomarkers

  • N/A

Drug/Treatment

  • bimekizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT03928743

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved